Abstract:Implementation of effective cancer treatment strategies requires consideration of how the spatiotemporal heterogeneities within the tumor microenvironment (TME) influence tumor progression and treatment response. Here, we developed a multi-scale three-dimensional mathematical model of the TME to simulate tumor growth and angiogenesis and then employed the model to evaluate an array of single and combination therapy approaches. Treatments included maximum tolerated dose or metronomic (i.e., frequent low doses) scheduling of anti-cancer drugs combined with anti-angiogenic therapy. The results show that metronomic therapy normalizes the tumor vasculature to improve drug delivery, modulates cancer metabolism, decreases interstitial fluid pressure and decreases cancer cell invasion. Further, we find that combining an anti-cancer drug with anti-angiogenic treatment enhances tumor killing and reduces drug accumulation in normal tissues. We also show that combined anti-angiogenic and anti-cancer drugs can decrease cancer invasiveness and normalize the cancer metabolic microenvironment leading to reduced hypoxia and hypoglycemia. Our model simulations suggest that vessel normalization combined with metronomic cytotoxic therapy has beneficial effects by enhancing tumor killing and limiting normal tissue toxicity. Effective treatment of solid tumors with injected drugs requires that sufficient exposure of cancer cells to the cytotoxic drugs. However, non-uniform and poorly functioning blood vessels make this difficult. The amount of drug that reaches a given cancer cells depends on many factors, including the drug chemistry, its lifetime in the blood circulation, its ability to cross the blood vessel wall and enter the tissue, and the schedule of the injections. We present a mathematical model of tumor growth, angiogenesis, metabolism and drug transport that examines how these processes affect the response to treatment. We find that low dose, high frequency (metronomic) therapy normalizes the tumor vasculature to improve drug delivery and that combining an anti-cancer drug with a drug that specifically enhances vascular function increases tumor killing and reduces drug accumulation in normal tissues. Our model simulations suggest that vessel normalization combined with metronomic cytotoxic therapy has beneficial effects by enhancing tumor killing and limiting normal tissue toxicity.

The impact of competition between cancer cells and healthy cells on optimal drug delivery

A Cancer Subpopulation Competition Model Reveals Optimal Levels of Immune Response that Minimize Tumor Size

Spatial structure impacts adaptive therapy by shaping intra-tumoral competition

Combination therapies and intra-tumoral competition: Insights from mathematical modeling

Simulations probe the role of space in the interplay between drug-sensitive and drug-resistant cancer cells

Investigating the development of chemotherapeutic drug resistance in cancer: A multiscale computational study

Optimal dosing of anti-cancer treatment under drug-induced plasticity

Do mechanisms matter? Comparing cancer treatment strategies across mathematical models and outcome objectives

A Mathematical Tumor Model with Immune Resistance and Drug Therapy: An Optimal Control Approach

Theoretical understanding of evolutionary dosing following tumor dynamics

Gaming the cancer-immunity cycle by synchronizing the dose schedules

Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates

Effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors

Pleiotropic effects of cell competition between normal and transformed cells in mammalian cancers

Stochastic competitive release and adaptive chemotherapy

A Comprehensive Model to Differentiate Spontaneous, Drug-induced, and CSCs-related Drug Resistance

A model of NSCLC microenvironment predicts optimal receptor targets

A spatial model of tumor-host interaction: Application of chemotherapy

The Optimization of Combination Chemotherapy Schedules in the Presence of Drug Resistance

Modeling three-dimensional invasive solid tumor growth in heterogeneous microenvironment under chemotherapy

Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization